Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III repeat vaccination study of AS25-adjuvanted influenza vaccine versus Fluarix in previously vaccinated adults
2007-002368-83Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-blind trial of GSK576389A and Fluarix in influenza (2 arms), sponsored by GSK. Primary endpoints: Solicited reactogenicity and safety within 21 days and Serious adverse events and medically significant conditions through Day 180. Started Jul 2007; status: completed.
02
Drugs
GSK576389AFluarix
03
Conditions
influenza
Beyond the preview
Go deeper on 2007-002368-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002368-83.